CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.


Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
05 2022
Historique:
received: 24 03 2021
accepted: 21 03 2022
pubmed: 6 5 2022
medline: 20 5 2022
entrez: 5 5 2022
Statut: ppublish

Résumé

Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) is characterized by clonal expansion of natural killer (NK) cells where the underlying genetic mechanisms are incompletely understood. In the present study, we report somatic mutations in the chemokine gene CCL22 as the hallmark of a distinct subset of CLPD-NK. CCL22 mutations were enriched at highly conserved residues, mutually exclusive of STAT3 mutations and associated with gene expression programs that resembled normal CD16

Identifiants

pubmed: 35513723
doi: 10.1038/s41588-022-01059-2
pii: 10.1038/s41588-022-01059-2
pmc: PMC9117519
mid: NIHMS1791505
doi:

Substances chimiques

Ccl22 protein, mouse 0
Chemokine CCL22 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

637-648

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM007267
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197695
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189859
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196172
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA044579
Pays : United States
Organisme : NLM NIH HHS
ID : T32 LM012416
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA232760
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178393
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA196040
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL136314
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM080202
Pays : United States

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375–2390 (2016).
pubmed: 26980727 pmcid: 4874220 doi: 10.1182/blood-2016-01-643569
Barila, G. et al. T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. Best. Pract. Res. Clin. Haematol. 32, 207–216 (2019).
pubmed: 31585621 doi: 10.1016/j.beha.2019.06.006
Lamy, T., Moignet, A. & Loughran, T. P. Jr LGL leukemia: from pathogenesis to treatment. Blood 129, 1082–1094 (2017).
pubmed: 28115367 doi: 10.1182/blood-2016-08-692590
Giussani, E. et al. Lack of viral load within chronic lymphoproliferative disorder of natural killer cells: what is outside the leukemic clone? Front Oncol. 10, 613570 (2020).
pubmed: 33585237 doi: 10.3389/fonc.2020.613570
Lamy, T. & Loughran, T. P. Jr How I treat LGL leukemia. Blood 117, 2764–2774 (2011).
pubmed: 21190991 pmcid: 3062292 doi: 10.1182/blood-2010-07-296962
Morice, W. G. et al. Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets. Leukemia 24, 881–884 (2010).
pubmed: 20111066 doi: 10.1038/leu.2009.304
Barila, G. et al. Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. Blood Cancer J. 8, 51 (2018).
pubmed: 29891951 pmcid: 6002482 doi: 10.1038/s41408-018-0088-1
Smith, S. L. et al. Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing. Blood Adv. 4, 1388–1406 (2020).
pubmed: 32271902 pmcid: 7160259 doi: 10.1182/bloodadvances.2019000699
Wagner, J. A. et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J. Clin. Invest. 127, 4042–4058 (2017).
pubmed: 28972539 pmcid: 5663359 doi: 10.1172/JCI90387
Michel, T. et al. Human CD56bright NK cells: an update. J. Immunol. 196, 2923–2931 (2016).
pubmed: 26994304 doi: 10.4049/jimmunol.1502570
Dogra, P. et al. Tissue determinants of human NK cell development, function, and residence. Cell 180, 749–763.e13 (2020).
pubmed: 32059780 pmcid: 7194029 doi: 10.1016/j.cell.2020.01.022
Koskela, H. L. et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 366, 1905–1913 (2012).
pubmed: 22591296 pmcid: 3693860 doi: 10.1056/NEJMoa1114885
Jerez, A. et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120, 3048–3057 (2012).
pubmed: 22859607 pmcid: 3471515 doi: 10.1182/blood-2012-06-435297
Gasparini, V. R. et al. A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. Blood Cancer J. 10, 42 (2020).
pubmed: 32321919 pmcid: 7176632 doi: 10.1038/s41408-020-0309-2
Pastoret, C. et al. Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells. Blood 137, 3237–3250 (2021).
Olson, T. L. et al. Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. Blood 138, 662–673 (2021).
pubmed: 33786584 doi: 10.1182/blood.2020005831
Cheon, H. et al. Analysis of genomic landscape of large granular lymphocyte leukemia reveals etiologic insights. Blood 136, 27–28 (2020).
doi: 10.1182/blood-2020-137269
Stengel, A., Meggendorfer, M., Kern, W., Haferlach, T. & Haferlach, C. Correlation of mutation patterns with patient age in 2656 cases with 11 different hematological malignancies. Blood 136, 16–17 (2020).
doi: 10.1182/blood-2020-136545
Jiang, L. et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat. Genet. 47, 1061–1066 (2015).
pubmed: 26192917 doi: 10.1038/ng.3358
Dufva, O. et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat. Commun. 9, 1567 (2018).
pubmed: 29674644 pmcid: 5908809 doi: 10.1038/s41467-018-03987-2
Scheu, S., Ali, S., Ruland, C., Arolt, V. & Alferink, J. The C-C chemokines CCL17 and CCL22 and their receptor CCR4 in CNS autoimmunity. Int. J. Mol. Sci. 18, 2306 (2017).
Homey, B., Steinhoff, M., Ruzicka, T. & Leung, D. Y. Cytokines and chemokines orchestrate atopic skin inflammation. J. Allergy Clin. Immunol. 118, 178–189 (2006).
pubmed: 16815153 doi: 10.1016/j.jaci.2006.03.047
Lucas, M., Schachterle, W., Oberle, K., Aichele, P. & Diefenbach, A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26, 503–517 (2007).
pubmed: 17398124 pmcid: 2084390 doi: 10.1016/j.immuni.2007.03.006
Anguille, S. et al. Interleukin-15 dendritic cells harness NK cell cytotoxic effector function in a contact- and IL-15-dependent manner. PLoS ONE 10, e0123340 (2015).
pubmed: 25951230 pmcid: 4423923 doi: 10.1371/journal.pone.0123340
Andoniou, C. E. et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat. Immunol. 6, 1011–1019 (2005).
pubmed: 16142239 doi: 10.1038/ni1244
Zambello, R. et al. Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood 106, 3926–3931 (2005).
pubmed: 16091452 doi: 10.1182/blood-2005-05-1972
Godiska, R. et al. Human macrophage–derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J. Exp. Med. 185, 1595–1604 (1997).
pubmed: 9151897 pmcid: 2196293 doi: 10.1084/jem.185.9.1595
Zheng, Y. et al. Structure of CC chemokine receptor 5 with a potent chemokine antagonist reveals mechanisms of chemokine recognition and molecular mimicry by HIV. Immunity 46, 1005–1017.e5 (2017).
pubmed: 28636951 pmcid: 5572563 doi: 10.1016/j.immuni.2017.05.002
Salanga, C. L. & Handel, T. M. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell. Res. 317, 590–601 (2011).
pubmed: 21223963 pmcid: 3089961 doi: 10.1016/j.yexcr.2011.01.004
Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377–389.e12 (2017).
pubmed: 28129538 pmcid: 5289311 doi: 10.1016/j.cell.2016.12.033
McCorvy, J. D. et al. Structural determinants of 5-HT2B receptor activation and biased agonism. Nat. Struct. Mol. Biol. 25, 787–796 (2018).
pubmed: 30127358 pmcid: 6237183 doi: 10.1038/s41594-018-0116-7
Yamashita, U. & Kuroda, E. Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit. Rev. Immunol. 22, 105–114 (2002).
pubmed: 12433129 doi: 10.1615/CritRevImmunol.v22.i2.10
Yoshie, O. & Matsushima, K. CCR4 and its ligands: from bench to bedside. Int. Immunol. 27, 11–20 (2014).
pubmed: 25087232 doi: 10.1093/intimm/dxu079
Mariani, M., Lang, R., Binda, E., Panina-Bordignon, P. & D’Ambrosio, D. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur. J. Immunol. 34, 231–240 (2004).
pubmed: 14971049 doi: 10.1002/eji.200324429
Rapp, M. et al. CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. J. Exp. Med. 216, 1170–1181 (2019).
pubmed: 30910796 pmcid: 6504218 doi: 10.1084/jem.20170277
Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004).
pubmed: 15322536 doi: 10.1038/nm1093
Mailloux, A. W. & Young, M. R. I. NK-dependent Increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J. Immunol. 182, 2753–2765 (2009).
pubmed: 19234170 doi: 10.4049/jimmunol.0801124
Nakagawa, M. et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J. Exp. Med. 211, 2497–2505 (2014).
pubmed: 25488980 pmcid: 4267233 doi: 10.1084/jem.20140987
Smith, J. S., Lefkowitz, R. J. & Rajagopal, S. Biased signalling: from simple switches to allosteric microprocessors. Nat. Rev. Drug Discov. 17, 243–260 (2018).
pubmed: 29302067 pmcid: 5936084 doi: 10.1038/nrd.2017.229
Lefkowitz, R. J. & Shenoy, S. K. Transduction of receptor signals by beta-arrestins. Science 308, 512–517 (2005).
pubmed: 15845844 doi: 10.1126/science.1109237
Drury, L. J. et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc. Natl Acad. Sci. USA 108, 17655–17660 (2011).
pubmed: 21990345 pmcid: 3203819 doi: 10.1073/pnas.1101133108
Bernardini, G., Sciume, G. & Santoni, A. Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow. Front. Immunol. 4, 12 (2013).
pubmed: 23386850 pmcid: 3558687 doi: 10.3389/fimmu.2013.00012
Wright, D. E., Bowman, E. P., Wagers, A. J., Butcher, E. C. & Weissman, I. L. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J. Exp. Med. 195, 1145–1154 (2002).
pubmed: 11994419 pmcid: 2193709 doi: 10.1084/jem.20011284
Eisenman, J. et al. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 20, 121–129 (2002).
pubmed: 12453470 doi: 10.1006/cyto.2002.1989
Costantini, C. et al. Neutrophil activation and survival are modulated by interaction with NK cells. Int. Immunol. 22, 827–838 (2010).
pubmed: 20739460 doi: 10.1093/intimm/dxq434
Thoren, F. B. et al. Human NK cells induce neutrophil apoptosis via an NKp46- and Fas-dependent mechanism. J. Immunol. 188, 1668–1674 (2012).
pubmed: 22231698 doi: 10.4049/jimmunol.1102002
Park, C. S., Yoon, S. O., Armitage, R. J. & Choi, Y. S. Follicular dendritic cells produce IL-15 that enhances germinal center B cell proliferation in membrane-bound form. J. Immunol. 173, 6676–6683 (2004).
pubmed: 15557159 doi: 10.4049/jimmunol.173.11.6676
Katakai, T. Marginal reticular cells: a stromal subset directly descended from the lymphoid tissue organizer. Front. Immunol. 3, 200 (2012).
pubmed: 22807928 pmcid: 3395019 doi: 10.3389/fimmu.2012.00200
Li, L., Wu, J., Abdi, R., Jewell, C. M. & Bromberg, J. S. Lymph node fibroblastic reticular cells steer immune responses. Trends Immunol. 42, 723–734 (2021).
pubmed: 34256989 pmcid: 8324561 doi: 10.1016/j.it.2021.06.006
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
Wang, Z. Q. et al. Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am. J. Hum. Genet 84, 672–677 (2009).
pubmed: 19375057 pmcid: 2680999 doi: 10.1016/j.ajhg.2009.03.019
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M. & Sexton, P. M. Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 19, 638–653 (2018).
pubmed: 30104700 doi: 10.1038/s41580-018-0049-3
Caligiuri, M. A. Human natural killer cells. Blood 112, 461–469 (2008).
pubmed: 18650461 pmcid: 2481557 doi: 10.1182/blood-2007-09-077438
Ali, A. K., Nandagopal, N. & Lee, S. H. IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells. Front. Immunol. 6, 355 (2015).
pubmed: 26257729 pmcid: 4507451 doi: 10.3389/fimmu.2015.00355
Mishra, A. et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 22, 645–655 (2012).
pubmed: 23153537 pmcid: 3627362 doi: 10.1016/j.ccr.2012.09.009
Ferlazzo, G. & Morandi, B. Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front. Immunol. 5, 159 (2014).
pubmed: 24782864 pmcid: 3989561 doi: 10.3389/fimmu.2014.00159
Liu, B. et al. Affinity-coupled CCL22 promotes positive selection in germinal centres. Nature 592, 133–137 (2021).
pubmed: 33597749 doi: 10.1038/s41586-021-03239-2
Bakker, E., Qattan, M., Mutti, L., Demonacos, C. & Krstic-Demonacos, M. The role of microenvironment and immunity in drug response in leukemia. Biochim. Biophys. Acta 1863, 414–426 (2016).
pubmed: 26255027 doi: 10.1016/j.bbamcr.2015.08.003
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Ajram, L. et al. Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists. Eur. J. Pharmacol. 729, 75–85 (2014).
pubmed: 24534492 pmcid: 3989064 doi: 10.1016/j.ejphar.2014.02.007
Mortier, E., Woo, T., Advincula, R., Gozalo, S. & Ma, A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J. Exp. Med. 205, 1213–1225 (2008).
pubmed: 18458113 pmcid: 2373851 doi: 10.1084/jem.20071913
Nandagopal, N., Ali, A. K., Komal, A. K. & Lee, S. H. The critical role of IL-15–PI3K–mTOR pathway in natural killer cell effector functions. Front. Immunol. 5, 187 (2014).
pubmed: 24795729 pmcid: 4005952 doi: 10.3389/fimmu.2014.00187
Crinier, A., Narni-Mancinelli, E., Ugolini, S. & Vivier, E. SnapShot: natural killer cells. Cell 180, 1280–1280.e1 (2020).
pubmed: 32200803 doi: 10.1016/j.cell.2020.02.029
Freud, A. G., Mundy-Bosse, B. L., Yu, J. & Caligiuri, M. A. The broad spectrum of human natural killer cell diversity. Immunity 47, 820–833 (2017).
pubmed: 29166586 pmcid: 5728700 doi: 10.1016/j.immuni.2017.10.008
Geiger, T. L. & Sun, J. C. Development and maturation of natural killer cells. Curr. Opin. Immunol. 39, 82–89 (2016).
pubmed: 26845614 pmcid: 4801705 doi: 10.1016/j.coi.2016.01.007
Gaggero, S., Witt, K., Carlsten, M. & Mitra, S. Cytokines orchestrating the natural killer–myeloid cell crosstalk in the tumor microenvironment: implications for natural killer cell-based cancer immunotherapy. Front. Immunol. 11, 621225 (2020).
pubmed: 33584718 doi: 10.3389/fimmu.2020.621225
Michel, T., Hentges, F. & Zimmer, J. Consequences of the crosstalk between monocytes/macrophages and natural killer cells. Front. Immunol. 3, 403 (2012).
pubmed: 23316194
Rohrle, N., Knott, M. M. L. & Anz, D. CCL22 signaling in the tumor environment. Adv. Exp. Med. Biol. 1231, 79–96 (2020).
pubmed: 32060848 doi: 10.1007/978-3-030-36667-4_8
Fehniger, T. A. et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8
pubmed: 11208862 pmcid: 2193336 doi: 10.1084/jem.193.2.219
Raczy, C. et al. Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. Bioinformatics 29, 2041–2043 (2013).
pubmed: 23736529 doi: 10.1093/bioinformatics/btt314
Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591–594 (2018).
pubmed: 30013048 doi: 10.1038/s41592-018-0051-x
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
pubmed: 32461654 pmcid: 7334197 doi: 10.1038/s41586-020-2308-7
Haferlach, T., Hutter, S. & Meggendorfer, M. Genome sequencing in myeloid cancers. N. Engl. J. Med. 384, e106 (2021).
pubmed: 34161717 doi: 10.1056/NEJMc2106014
Hutter, S. et al. A novel machine learning based in silico pathogenicity predictor for missense variants in a hematological setting Blood 134, 2090 (2019).
Parida, L. et al. Dark-matter matters: discriminating subtle blood cancers using the darkest DNA. PLoS Comput. Biol. 15, e1007332 (2019).
pubmed: 31469830 pmcid: 6742441 doi: 10.1371/journal.pcbi.1007332
Zhou, X. et al. Exploration of coding and non-coding variants in cancer using GenomePaint. Cancer Cell 39, 83–95.e4 (2021).
pubmed: 33434514 pmcid: 7884056 doi: 10.1016/j.ccell.2020.12.011
Dogra, P. et al. Tissue determinants of human NK. Cell Dev. Funct. Resid. Cell 180, 749–763.e13 (2020).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
pubmed: 25260700 doi: 10.1093/bioinformatics/btu638
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882–883 (2012).
pubmed: 22257669 pmcid: 3307112 doi: 10.1093/bioinformatics/bts034
Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).
pubmed: 30944313 pmcid: 6447622 doi: 10.1038/s41467-019-09234-6
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Konagurthu, A. S., Whisstock, J. C., Stuckey, P. J. & Lesk, A. M. MUSTANG: a multiple structural alignment algorithm. Proteins 64, 559–574 (2006).
pubmed: 16736488 doi: 10.1002/prot.20921
Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
pubmed: 21988835 pmcid: 3261699 doi: 10.1038/msb.2011.75
Valdar, W. S. Scoring residue conservation. Proteins 48, 227–241 (2002).
pubmed: 12112692 doi: 10.1002/prot.10146
Wagih, O. ggseqlogo: a versatile R package for drawing sequence logos. Bioinformatics 33, 3645–3647 (2017).
pubmed: 29036507 doi: 10.1093/bioinformatics/btx469
Liu, D., Paczkowski, P., Mackay, S., Ng, C. & Zhou, J. Single-cell multiplexed proteomics on the IsoLight resolves cellular functional heterogeneity to reveal clinical responses of cancer patients to immunotherapies. Methods Mol. Biol. 2055, 413–431 (2020).
pubmed: 31502163 doi: 10.1007/978-1-4939-9773-2_19
Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477–6489 (2005).
pubmed: 15879151 doi: 10.4049/jimmunol.174.10.6477
Aickin, M. & Gensler, H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am. J. Public Health 86, 726–728 (1996).
pubmed: 8629727 pmcid: 1380484 doi: 10.2105/AJPH.86.5.726

Auteurs

Constance Baer (C)

MLL Munich Leukemia Laboratory, Munich, Germany.

Shunsuke Kimura (S)

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. shunsuke.kimura@stjude.org.

Mitra S Rana (MS)

Protein Technologies Center, Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Andrew B Kleist (AB)

Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
Medical Scientist Training Program, Medical College of Wisconsin, Milwaukee, WI, USA.

Tim Flerlage (T)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.

David J Feith (DJ)

University of Virginia Cancer Center, Charlottesville, VA, USA.
Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.

Peter Chockley (P)

Department of Bone Marrow Transplantation & Cell Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.

Wencke Walter (W)

MLL Munich Leukemia Laboratory, Munich, Germany.

Manja Meggendorfer (M)

MLL Munich Leukemia Laboratory, Munich, Germany.

Thomas L Olson (TL)

University of Virginia Cancer Center, Charlottesville, VA, USA.
Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.

HeeJin Cheon (H)

University of Virginia Cancer Center, Charlottesville, VA, USA.
Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Medical Scientist Training Program, University of Virginia School of Medicine, Charlottesville, VA, USA.

Kristine C Olson (KC)

University of Virginia Cancer Center, Charlottesville, VA, USA.
Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.

Aakrosh Ratan (A)

University of Virginia Cancer Center, Charlottesville, VA, USA.
Medical Scientist Training Program, University of Virginia School of Medicine, Charlottesville, VA, USA.
Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA.

Martha-Lena Mueller (ML)

MLL Munich Leukemia Laboratory, Munich, Germany.

James M Foran (JM)

Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.

Laura J Janke (LJ)

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Chunxu Qu (C)

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Shaina N Porter (SN)

Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Shondra M Pruett-Miller (SM)

Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Ravi C Kalathur (RC)

Protein Technologies Center, Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Claudia Haferlach (C)

MLL Munich Leukemia Laboratory, Munich, Germany.

Wolfgang Kern (W)

MLL Munich Leukemia Laboratory, Munich, Germany.

Elisabeth Paietta (E)

Department of Oncology, Montefiore Medical Center, Bronx, NY, USA.

Paul G Thomas (PG)

Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.

M Madan Babu (MM)

Center of Excellence for Data Driven Discovery, Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Thomas P Loughran (TP)

University of Virginia Cancer Center, Charlottesville, VA, USA.
Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.

Ilaria Iacobucci (I)

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. ilaria.iacobucci@stjude.org.

Torsten Haferlach (T)

MLL Munich Leukemia Laboratory, Munich, Germany. torsten.haferlach@mll.com.

Charles G Mullighan (CG)

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. charles.mullighan@stjude.org.
Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN, USA. charles.mullighan@stjude.org.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH